Analysts Set Oculis Holding AG (NASDAQ:OCS) PT at $41.50

Shares of Oculis Holding AG (NASDAQ:OCS) have received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $43.50.

Several brokerages recently issued reports on OCS. Chardan Capital reissued a “buy” rating and issued a $51.00 price objective on shares of Oculis in a research note on Tuesday, November 11th. Lifesci Capital assumed coverage on shares of Oculis in a research report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price target for the company. Stifel Nicolaus upped their price objective on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. started coverage on shares of Oculis in a research report on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price for the company. Finally, Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of OCS. Geode Capital Management LLC raised its stake in shares of Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Oculis in the 2nd quarter valued at approximately $393,000. Bosun Asset Management LLC acquired a new position in Oculis in the second quarter worth approximately $378,000. Bank of America Corp DE raised its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after acquiring an additional 33,265 shares during the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Stock Down 2.8%

OCS stock opened at $26.96 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 4.47. The firm has a market capitalization of $1.56 billion, a P/E ratio of -11.88 and a beta of 0.29. Oculis has a 52-week low of $14.00 and a 52-week high of $30.68. The company’s 50 day simple moving average is $26.16 and its 200-day simple moving average is $21.55.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. As a group, equities research analysts anticipate that Oculis will post -2.09 EPS for the current year.

Trending Headlines about Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Company is actively presenting at multiple investor conferences in March and reiterated late‑stage pipeline milestones — Privosegtor received breakthrough therapy designation (optic neuritis), OCS‑01 topline readout expected in Q2 2026, and Licaminlimab advancing as a genotype‑driven program — supporting longer‑term upside for the stock. Oculis to Participate in Upcoming Investor Conferences
• Positive Sentiment: HC Wainwright raised a price target to $44 (published by AmericanBankingNews), which can provide technical/psychological support despite other model reductions. HC Wainwright Boosts Oculis Price Target
• Neutral Sentiment: Oculis filed its audited 2025 consolidated financial statements and MD&A on Form 20‑F — useful for diligence but largely informational unless the filings reveal unexpected surprises. Oculis Publishes 2025 Consolidated Financial Statements
• Neutral Sentiment: Company published notifications that RSUs granted to directors have vested and been settled — standard disclosure; could be neutral if shares are retained, or slightly negative if it leads to insider selling. Oculis Publishes Notifications of Transactions
• Negative Sentiment: Multiple analyst teams (LifeSci Capital and HC Wainwright) cut near‑term quarterly and FY2026 EPS forecasts, trimming expectations for Q1–Q4 and lowering FY numbers — these downward revisions increase near‑term earnings uncertainty and likely triggered selling pressure. (Analyst notes summarized on MarketBeat.) Analyst Estimate Reductions

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.